GGrantIndex
← Leaderboards

Zuoshang Xu

Univ Of Massachusetts Med Sch Worcester

Google Scholar ↗PubMed ↗ORCID ↗
$14,371,059
Attributed
$15,498,083
Total exposure
19
Grants
14
Lead (contact PI)

Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.

Funding over time

peak $1.7M · FY2005–25
$2M$1.5M$1M$500K$0
'05
'06
'07
'08
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25

Funding mix

By agency

NIH$15,498,083 · 19

By mechanism

R01$9,390,722 · 6
R21$5,107,762 · 12
RC1$999,599 · 1

Top collaborators

Most similar at Univ Of Massachusetts Med Sch Worcester

Same institution · by research overlap

Others in their field

Top investigators on “Amyotrophic Lateral Sclerosis”

Research focus

Amyotrophic Lateral SclerosisNeurodegenerative DisordersMutantMotor NeuronsMouse ModelCessation Of LifeParalysedGenesIn VivoAnimal ModelGene MutationMutationMotor Neuron DegenerationProteinsSpinal CordTransgenic OrganismsBaseNerve DegenerationRna InterferenceNeuronsToxic EffectCellsPhenotypeTransgenic Mice

Grant awards (50)

Protein Arginine Deiminase 2 (PAD2) and Protein Citrullination in ALS$487,663
R01 · FY2025 · NS · contact PI
Investigating the role of TDP-43 citrullination in ALS pathogenesis$460,625
R21 · FY2025 · NS
Protein Arginine Deiminase 2 (PAD2) and Protein Citrullination in ALS$473,033
R01 · FY2024 · NS · contact PI
Protein Arginine Deiminase 2 (PAD2) and Protein Citrullination in ALS$487,663
R01 · FY2023 · NS · contact PI
Protein Arginine Deiminase 2 (PAD2) and Protein Citrullination in ALS$487,663
R01 · FY2022 · NS · contact PI
Protein Arginine Deiminase 2 (PAD2) and Protein Citrullination in ALS$487,663
R01 · FY2021 · NS · contact PI
An in vivo approach to understanding mutant PFN1 toxicity on motor neurons$366,406
R01 · FY2021 · NS · contact PI
An in vivo approach to understanding mutant PFN1 toxicity on motor neurons$366,406
R01 · FY2020 · NS · contact PI
A new approach to immunotherapy for ALS$460,625
R21 · FY2019 · NS · contact PI
An in vivo approach to understanding mutant PFN1 toxicity on motor neurons$366,406
R01 · FY2019 · NS · contact PI
An in vivo approach to understanding mutant PFN1 toxicity on motor neurons$366,406
R01 · FY2018 · NS · contact PI
An in vivo approach to understanding mutant PFN1 toxicity on motor neurons$335,000
R01 · FY2017 · NS · contact PI
A new approach to modeling ALS based on TBK1 mutation in mice$209,375
R21 · FY2017 · NS · contact PI
A new antibody/RNAi combination therapy strategy for ALS$251,250
R21 · FY2016 · NS · contact PI
A new approach to modeling ALS based on TBK1 mutation in mice$251,250
R21 · FY2016 · NS · contact PI
Does TDP-43 dysfunction in astrocytes trigger motor neuron degeneration?$251,250
R21 · FY2016 · NS · contact PI
A new antibody/RNAi combination therapy strategy for ALS$209,375
R21 · FY2015 · NS · contact PI
Does TDP-43 dysfunction in astrocytes trigger motor neuron degeneration?$209,375
R21 · FY2015 · NS · contact PI
Modeling Mutant Profilin 1 Toxicity and ALS in vivo$248,366
R21 · FY2014 · NS · contact PI
Modeling Mutant Profilin 1 Toxicity and ALS in vivo$207,969
R21 · FY2013 · NS · contact PI
Transgenic models of ALS caused by VAPB mutation$348,359
R01 · FY2012 · NS · contact PI
Transgenic models of ALS caused by VAPB mutation$348,359
R01 · FY2011 · NS · contact PI
Transgenic Mouse Models of FUS/TLS-Mediated Amyotrophic Lateral Sclerosis$499,740
RC1 · FY2010 · NS
Transgenic models of ALS caused by VAPB mutation$351,915
R01 · FY2010 · NS · contact PI
Transgenic Mouse Models of FUS/TLS-Mediated Amyotrophic Lateral Sclerosis$499,859
RC1 · FY2009 · NS
Transgenic models of ALS caused by VAPB mutation$355,469
R01 · FY2009 · NS · contact PI
Understanding CLIM2 functions in vivo using transgenic RNAi$245,938
R21 · FY2009 · RR · contact PI
Modeling TDP-43 Dysfunction in vivo$213,281
R21 · FY2009 · NS · contact PI
Transgenic models of ALS caused by VAPB mutation$355,469
R01 · FY2008 · NS · contact PI
Understanding mechanism and therapy of ALS using RNAi$348,635
R01 · FY2008 · NS · contact PI
Modeling Progranulin hypomorphism for FTD in mice$213,281
R21 · FY2008 · NS · contact PI
Understanding CLIM2 functions in vivo using transgenic RNAi$204,323
R21 · FY2008 · RR · contact PI
Reverse genetics using RNAi in non-mouse mammals$195,878
R21 · FY2008 · AG · contact PI
Silencing mutant SOD1 in vivo for treatment of ALS$178,403
R21 · FY2008 · NS · contact PI
Modeling TDP-43 Dysfunction in vivo$177,734
R21 · FY2008 · NS · contact PI
Understanding mechanism and therapy of ALS using RNAi$348,635
R01 · FY2007 · NS · contact PI
Silencing mutant SOD1 in vivo for treatment of ALS$228,164
R21 · FY2007 · NS · contact PI
Modeling Progranulin hypomorphism for FTD in mice$177,734
R21 · FY2007 · NS · contact PI
Reverse genetics using RNAi in non-mouse mammals$166,563
R21 · FY2007 · AG · contact PI
Understanding mechanism and therapy of ALS using RNAi$359,047
R01 · FY2006 · NS · contact PI
Understanding mechanism and therapy of ALS using RNAi$367,688
R01 · FY2005 · NS
Developing animal models for diseases using RNAi$189,540
R21 · FY2005 · AG
Understanding mechanism and therapy of ALS using RNAi$367,688
R01 · FY2004 · NS
Developing animal models for diseases using RNAi$157,463
R21 · FY2004 · AG
Mitochondrial dysfunction in ALS$198,750
R01 · FY2003 · NS
DISEASE PROGRESSION AND OXIDATIVE STRESS IN ALS$343,247
R01 · FY2002 · NS
Mitochondrial dysfunction in ALS$198,334
R01 · FY2002 · NS
DISEASE PROGRESSION AND OXIDATIVE STRESS IN ALS$333,246
R01 · FY2001 · NS
Mitochondrial dysfunction in ALS$218,030
R01 · FY2001 · NS
DISEASE PROGRESSION AND OXIDATIVE STRESS IN ALS$323,542
R01 · FY2000 · NS